Torcetrapib - CAS:262352-17-0

您当前的位置：

Torcetrapib (Synonyms:托彻普; CP-529414)

目录号 : KM3593 CAS No. : 262352-17-0 纯度 : 98%

Data Sheet 产品使用指南

Torcetrapib (CP-529414) 是一种选择性、有效的胆固醇酯转移蛋白 (CETP) 抑制剂。在人血浆的抑制曲线中对CETP的最有效浓度为 37 nM。

规格	价格	是否有货
5mg		In-stock
10mg		In-stock
50mg		In-stock
100mg	询价	In-stock
200mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Dydrogesterone-D6 In-stock
Prostaglandin E1-d4 In-stock
Norcholic acid In-stock
Dicyclohexyl phthalate-3,4,5,6-d4 In-stock
Mebhydrolin napadisylate In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM.

体外研究

The IC₅₀ for Torcetrapib determined from the linear portion of the curves (25 to 80 nM) is 52 and 65 nM for the H-HDL and C-LDL cholesteryl ester transfer assays, respectively, using the specific activity-adjusted calculation, and 47 and 61 nM using a single exponential decay function.
Torcetrapib (0, 0.5, 1, 5, and 10 μM) significantly reduced MCF-7 cells growth.
Torcetrapib (0, 1, 5, 10, and 20 μM) does not inducing MCF-7 cells apoptosis.
Torcetrapib (10 μM) binds to CETP with high affinity and down-regulates CETP expression.

Cell Viability Assay

Cell Line:	MCF-7 cells
Concentration:	0, 0.5, 1, 5, and 10 μM
Incubation Time:	5 days
Result:	Significantly reduced cell growth.

RT-PCR

Cell Line:	MCF-7 cells
Concentration:	10 μM
Incubation Time:	48 hours
Result:	Down-regulated CETP mRNA expression.

体内研究

Torcetrapib (3, 10, or 30 mg/kg every day [qd]; oral gavage for 14 days) significantly increases high-density lipoprotein (HDL) cholesterol and reduceslow-density lipoprotein (LDL) cholesterol, and there is a tendency for Torcetrapib to reduce very-low-density lipoprotein (VLDL) cholesterol and triglycerides. Maximal increase in HDL cholesterol is 53% with Torcetrapib.

Animal Model:	Male Tg (B6; SJL-TgN (CETP)-TgN (ApoB100)) mice at 6 to 7 weeks of age
Dosage:	3, 10, and 30 mg/kg
Administration:	Orally every day for 14 days
Result:	Significantly Increased HDL cholesterol by 27%, 24%, and 53% in the 3, 10, and 30 mg/kg groups compared to baseline, respectively, after 14 days of treatment. Significantly decreased LDL cholesterol by 44% and 35% at 10 and 30 mg/kg compared to baseline, respectively, after 14 days of treatment.

分子式

C₂₆H₂₅N₂O₄F₉

分子量

600.47

CAS号

262352-17-0

中文名称

托彻普；托斯瑞比

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (166.54 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6654 mL	8.3268 mL	16.6536 mL
5 mM	0.3331 mL	1.6654 mL	3.3307 mL
10 mM	0.1665 mL	0.8327 mL	1.6654 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.16 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.16 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。